Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low?

• References

• 1 Schimpf K, Schwarz HP, Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 546-556
• 2 Roberts HR, Cromartie R. Overview of inhibitors to factors VIII and IX. Progr Clin Biol Res 1984; 150: 1-19
• 3 Hanley JA, Lippman-Hand A. If nothing is wrong, is everything all right? Interpreting studies with zero numerators. JAMA 1983; 249: 1743-1745
• 4 Briät R, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A: a meta-analysis based on eight long-term follow up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 162-163